Voltage-gated calcium channel alpha1 subunit (Cav alpha1) (Cav alpha1)

The voltage-gated calcium channel alpha1 subunit is the primary, pore-forming component of the voltage-gated calcium channel (VGCC) complex, responsible for calcium ion selectivity, conductance, and voltage sensing (UniProt [1], PubMed [4]). It consists of four homologous domains, each containing six transmembrane segments, and determines the fundamental pharmacological and electrophysiological characteristics of the channel (IUPHAR [3], PubMed [4]). These subunits are classified into three major families: Cav1 (mediating L-type currents), Cav2 (mediating P/Q-, N-, and R-type currents), and Cav3 (mediating T-type currents) (IUPHAR [3]). They play essential roles in coupling electrical signals at the cell surface to physiological responses, such as muscle contraction, neurotransmitter release, and gene transcription (StatPearls [2], PubMed [4]). Dysregulation or mutations in these subunits are implicated in a wide range of diseases, including hypertension, cardiac arrhythmias, epilepsy, and chronic pain (StatPearls [2], IUPHAR [3]). Consequently, they serve as critical therapeutic targets for various drugs, including dihydropyridines, phenylalkylamines, and benzothiazepines, which modulate calcium entry to treat cardiovascular and neurological conditions (StatPearls [2], PubMed [4]).

Other names

CACNA1Calcium channel alpha-1 subunitPore-forming calcium channel subunitCaV1 alpha1 subunitCaV2 alpha1 subunitCaV3 alpha1 subunit

Drugs targeting the alpha1 subunit typically act as pore blockers or allosteric modulators that inhibit the influx of calcium ions into the cell. By binding to specific sites on the alpha1 subunit, these agents prevent the conformational changes required for channel opening or physically obstruct the pore, thereby reducing intracellular calcium concentrations and dampening cellular excitability (StatPearls [2], PubMed [4]).